These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25349080)

  • 1. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
    Hershman DL; Tsui J; Meyer J; Glied S; Hillyer GC; Wright JD; Neugut AI
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25349080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer.
    Neugut AI; Subar M; Wilde ET; Stratton S; Brouse CH; Hillyer GC; Grann VR; Hershman DL
    J Clin Oncol; 2011 Jun; 29(18):2534-42. PubMed ID: 21606426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
    Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
    J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
    Neuner JM; Kamaraju S; Charlson JA; Wozniak EM; Smith EC; Biggers A; Smallwood AJ; Laud PW; Pezzin LE
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of generic aromatase inhibitors on initiation, adherence, and persistence among women with breast cancer: Applying multi-state models to understand the dynamics of adherence.
    Winn AN; Fergestrom NM; Pezzin LE; Laud PW; Neuner JM
    Pharmacoepidemiol Drug Saf; 2020 May; 29(5):550-557. PubMed ID: 32196839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer.
    Ma S; Shepard DS; Ritter GA; Martell RE; Thomas CP
    Cancer; 2020 Aug; 126(15):3417-3425. PubMed ID: 32484941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.
    Hershman DL; Tsui J; Wright JD; Coromilas EJ; Tsai WY; Neugut AI
    J Clin Oncol; 2015 Mar; 33(9):1053-9. PubMed ID: 25691670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate.
    Mager DE; Cox ER
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):347-52. PubMed ID: 17567235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit.
    Spence MM; Hui R; Chan J
    J Manag Care Pharm; 2006 Jun; 12(5):377-82. PubMed ID: 16792444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.
    Haque R; Ahmed SA; Fisher A; Avila CC; Shi J; Guo A; Craig Cheetham T; Schottinger JE
    Cancer Med; 2012 Dec; 1(3):318-27. PubMed ID: 23342281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
    Sedjo RL; Devine S
    Breast Cancer Res Treat; 2011 Jan; 125(1):191-200. PubMed ID: 20495864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.
    Aiello Bowles EJ; Boudreau DM; Chubak J; Yu O; Fujii M; Chestnut J; Buist DS
    J Oncol Pract; 2012 Nov; 8(6):e149-57. PubMed ID: 23598850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
    Doshi JA; Li P; Desai S; Marcus SC
    J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost sharing for breast cancer hormone therapy: How do dual eligible patients' copayment impact adherence.
    Ma S; Shepard DS; Ritter GA; Martell RE; Thomas CP
    PLoS One; 2021; 16(5):e0250967. PubMed ID: 34003865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Chen J; Mao JJ
    Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.
    Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
    Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.
    Neugut AI; Zhong X; Wright JD; Accordino M; Yang J; Hershman DL
    JAMA Oncol; 2016 Oct; 2(10):1326-1332. PubMed ID: 27281650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
    Chin AL; Bentley JP; Pollom EL
    Cancer; 2019 Feb; 125(3):374-381. PubMed ID: 30566762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.